Platinum sponsor

Cannabinoid Education 360, developed by GW Pharmaceuticals

Cannabinoid Education 360 is a new educational initiative that delivers easily accessible, evidence-based, balanced information on cannabinoids and cannabis-based medicines and products.

Our ambition is to provide a full 360-degree perspective on what is really known about the science of cannabinoids, the research behind cannabis-based medicines, and the laws and policy frameworks that regulate them. We want to help dispel any myths and provide clarity around this important, yet complex field of medicine. 

GW Pharmaceuticals (GW), part of Jazz Pharmaceuticals, is a pioneering, global biopharmaceutical company that over the last 20 years has established a world-leading position in cannabinoid science and medicines. GW’s mission is to transform the lives of patients with rare and severe illnesses through developing and delivering rigorously tested cannabinoid-based pharmaceutical medicines with well documented safety and efficacy profiles, manufactured to the highest pharmaceutical standards and approved by medicines regulators.


Education in neurology


Sovereign House -Vision Park, Histon -Cambridge -CB24 9BZ – United Kingdom

SILVER sponsorS


Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving
antibiotics, antimalarials and cancer medicines. Moreover, for the twelfth consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2019 employed about 98,000 people worldwide. In 2019, Roche invested CHF 11.7 billion in R&D and posted sales of CHF 61.5 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit

Tianqiao and Chrissy Chen Institute

The Tianqiao and Chrissy Chen Institute (TCCI) was created in 2016 by Tianqiao Chen and his wife Chrissy Luo, the founders of Shanda Group, with a US $1 billion commitment to help advance fundamental brain research. TCCI created the Tianqiao and Chrissy Chen Institute for Neuroscience at Caltech later that year with a US $115 million donation. In 2017, the couple committed CNY 500 million to create the Tianqiao and Chrissy Chen Institute for Translational Research, a partnership with the Zhou Liangfu Foundation, Huashan Hospital and Shanghai Mental Health Center. In October 2020, the organization opened its first Frontier Lab for Brain Science which is embedded at Huashan Hospital’s new Hongqiao campus. Its second Frontier Lab was opened within Shanghai Mental Health Center in July 2021.


Follow TCCI news at, on LinkedIn, or via Twitter @ChenInstitute.

Watch TCCI’s award-winning documentary at


ICONEUS is a start-up company developing and commercializing a breakthrough ultrasound-based brain imaging modality (functional ultrasound imaging or fUS). This revolutionary method allows the visualization of brain activity with unprecedented spatial and temporal resolution and high sensitivity. Founded in 2016, ICONEUS sells products dedicated to neuroscience all over the world and aims to become the world leader in neuro-functional imaging. Data processing in medical imaging technologies is one of our key strengths which allows us to bring breakthrough technologies to the research equipment market in neurosciences. We are a talented team based in Paris, where experts in Neuroscience, Ultrasound Physics, and  software engineering work side-by-side to develop new product features and to fine-tune the technology for emerging applications. We are strongly committed to developing innovative medical imaging data processing technologies.